190 related articles for article (PubMed ID: 35151844)
1. HSP90-CDC37 functions as a chaperone for the oncogenic FGFR3-TACC3 fusion.
Li T; Mehraein-Ghomi F; Forbes ME; Namjoshi SV; Ballard EA; Song Q; Chou PC; Wang X; Parker Kerrigan BC; Lang FF; Lesser G; Debinski W; Yang X; Zhang W
Mol Ther; 2022 Apr; 30(4):1610-1627. PubMed ID: 35151844
[TBL] [Abstract][Full Text] [Related]
2. Targeting CDC37: an alternative, kinase-directed strategy for disruption of oncogenic chaperoning.
Smith JR; Workman P
Cell Cycle; 2009 Feb; 8(3):362-72. PubMed ID: 19177013
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast growth factor receptor 3 (FGFR3) is a strong heat shock protein 90 (Hsp90) client: implications for therapeutic manipulation.
Laederich MB; Degnin CR; Lunstrum GP; Holden P; Horton WA
J Biol Chem; 2011 Jun; 286(22):19597-604. PubMed ID: 21487019
[TBL] [Abstract][Full Text] [Related]
4. A metabolic function of FGFR3-TACC3 gene fusions in cancer.
Frattini V; Pagnotta SM; Tala ; Fan JJ; Russo MV; Lee SB; Garofano L; Zhang J; Shi P; Lewis G; Sanson H; Frederick V; Castano AM; Cerulo L; Rolland DCM; Mall R; Mokhtari K; Elenitoba-Johnson KSJ; Sanson M; Huang X; Ceccarelli M; Lasorella A; Iavarone A
Nature; 2018 Jan; 553(7687):222-227. PubMed ID: 29323298
[TBL] [Abstract][Full Text] [Related]
5. Precise editing of FGFR3-TACC3 fusion genes with CRISPR-Cas13a in glioblastoma.
Wu Y; Jin W; Wang Q; Zhou J; Wang Y; Tan Y; Cui X; Tong F; Yang E; Wang J; Kang C
Mol Ther; 2021 Nov; 29(11):3305-3318. PubMed ID: 34274537
[TBL] [Abstract][Full Text] [Related]
6. Dynamic tyrosine phosphorylation modulates cycling of the HSP90-P50(CDC37)-AHA1 chaperone machine.
Xu W; Mollapour M; Prodromou C; Wang S; Scroggins BT; Palchick Z; Beebe K; Siderius M; Lee MJ; Couvillon A; Trepel JB; Miyata Y; Matts R; Neckers L
Mol Cell; 2012 Aug; 47(3):434-43. PubMed ID: 22727666
[TBL] [Abstract][Full Text] [Related]
7. p50(cdc37) acting in concert with Hsp90 is required for Raf-1 function.
Grammatikakis N; Lin JH; Grammatikakis A; Tsichlis PN; Cochran BH
Mol Cell Biol; 1999 Mar; 19(3):1661-72. PubMed ID: 10022854
[TBL] [Abstract][Full Text] [Related]
8. Cdc37 (cell division cycle 37) restricts Hsp90 (heat shock protein 90) motility by interaction with N-terminal and middle domain binding sites.
Eckl JM; Rutz DA; Haslbeck V; Zierer BK; Reinstein J; Richter K
J Biol Chem; 2013 May; 288(22):16032-42. PubMed ID: 23569206
[TBL] [Abstract][Full Text] [Related]
9. Hsp90/Cdc37 chaperone/co-chaperone complex, a novel junction anticancer target elucidated by the mode of action of herbal drug Withaferin A.
Grover A; Shandilya A; Agrawal V; Pratik P; Bhasme D; Bisaria VS; Sundar D
BMC Bioinformatics; 2011 Feb; 12 Suppl 1(Suppl 1):S30. PubMed ID: 21342561
[TBL] [Abstract][Full Text] [Related]
10. Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors.
Smith JR; Clarke PA; de Billy E; Workman P
Oncogene; 2009 Jan; 28(2):157-69. PubMed ID: 18931700
[TBL] [Abstract][Full Text] [Related]
11. Specific regulation of noncanonical p38alpha activation by Hsp90-Cdc37 chaperone complex in cardiomyocyte.
Ota A; Zhang J; Ping P; Han J; Wang Y
Circ Res; 2010 Apr; 106(8):1404-12. PubMed ID: 20299663
[TBL] [Abstract][Full Text] [Related]
12. RNAi technology targeting the
Parker Kerrigan BC; Ledbetter D; Kronowitz M; Phillips L; Gumin J; Hossain A; Yang J; Mendt M; Singh S; Cogdell D; Ene C; Shpall E; Lang FF
Neurooncol Adv; 2020; 2(1):vdaa132. PubMed ID: 33241214
[TBL] [Abstract][Full Text] [Related]
13. Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy.
Xu J; Wu PJ; Lai TH; Sharma P; Canella A; Welker AM; Beattie CE; Elder JB; Easley M; Lonser R; Jacob NK; Pietrzak M; Timmers CM; Lang F; Sampath D; Puduvalli VK
Clin Cancer Res; 2022 May; 28(9):1979-1990. PubMed ID: 35140124
[TBL] [Abstract][Full Text] [Related]
14. Cell Stress Induced Stressome Release Including Damaged Membrane Vesicles and Extracellular HSP90 by Prostate Cancer Cells.
Eguchi T; Sogawa C; Ono K; Matsumoto M; Tran MT; Okusha Y; Lang BJ; Okamoto K; Calderwood SK
Cells; 2020 Mar; 9(3):. PubMed ID: 32204513
[TBL] [Abstract][Full Text] [Related]
15. The driver of malignancy in KG-1a leukemic cells, FGFR1OP2-FGFR1, encodes an HSP90 addicted oncoprotein.
Jin Y; Zhen Y; Haugsten EM; Wiedlocha A
Cell Signal; 2011 Nov; 23(11):1758-66. PubMed ID: 21745565
[TBL] [Abstract][Full Text] [Related]
16. HSP90-CDC37-PP5 forms a structural platform for kinase dephosphorylation.
Oberoi J; Guiu XA; Outwin EA; Schellenberger P; Roumeliotis TI; Choudhary JS; Pearl LH
Nat Commun; 2022 Nov; 13(1):7343. PubMed ID: 36446791
[TBL] [Abstract][Full Text] [Related]
17. Disease Variants of FGFR3 Reveal Molecular Basis for the Recognition and Additional Roles for Cdc37 in Hsp90 Chaperone System.
Bunney TD; Inglis AJ; Sanfelice D; Farrell B; Kerr CJ; Thompson GS; Masson GR; Thiyagarajan N; Svergun DI; Williams RL; Breeze AL; Katan M
Structure; 2018 Mar; 26(3):446-458.e8. PubMed ID: 29478821
[TBL] [Abstract][Full Text] [Related]
18. Expression and purification of recombinant NRL-Hsp90α and Cdc37-CRL proteins for in vitro Hsp90/Cdc37 inhibitors screening.
He J; Niu X; Hu C; Zhang H; Guo Y; Ge Y; Wang G; Jiang Y
Protein Expr Purif; 2013 Nov; 92(1):119-27. PubMed ID: 24056254
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas.
Canella A; Welker AM; Yoo JY; Xu J; Abas FS; Kesanakurti D; Nagarajan P; Beattie CE; Sulman EP; Liu J; Gumin J; Lang FF; Gurcan MN; Kaur B; Sampath D; Puduvalli VK
Clin Cancer Res; 2017 Oct; 23(20):6215-6226. PubMed ID: 28679777
[No Abstract] [Full Text] [Related]
20. Medium-Throughput Detection of Hsp90/Cdc37 Protein-Protein Interaction Inhibitors Using a Split
Siddiqui FA; Parkkola H; Manoharan GB; Abankwa D
SLAS Discov; 2020 Feb; 25(2):195-206. PubMed ID: 31662027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]